Company Overview and News

to your dashboard

Headline News

2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?

2018-01-16 seekingalpha
Significant scientific and technological breakthroughs, combined with unabated M&A appetite and tax reform, provide fertile ground for biotech gains in 2018. (302-4)

Zymeworks - Protein Proficiency At A Discount

2018-01-09 seekingalpha
The company's internal candidates are highly promising, reinforcing the value proposition of the company's software platform. (115-1)

ROTY Edition 1 Volume 68: An Exciting New Position And Other Updates

2018-01-08 seekingalpha
The JPMorgan Healthcare Conference is a significant event that readers interested in the sector should pay close attention to. (66-3)

Biotech Analysis Central Pharma News: Protalix Phase 2 Success, Achaogen NDA Acceptance, GW Pharmaceuticals FDA Advance

2018-01-03 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (113-5)

Achaogen's NDA for Plazomicin Gets Priority Review From FDA

2018-01-03 zacks
Achaogen, Inc. (AKAO - Free Report) announced that the FDA has accepted its new drug application (“NDA”) for its urinary tract infections candidate, plazomicin. The FDA has also granted priority review to the NDA, which will expedite the review process. A decision is expected on Jun 25, 2018. (117-3)

ROTY Edition 1 Volume 67: Starting January On A Strong Note

2018-01-03 seekingalpha
ROTY had a solid December and January appears to be starting on a strong note as well. (107-1)

Your Daily Pharma Scoop: Achaogen Is A Compelling Investment, Protalix Gains On Preliminary Results, BioTime Announces Publication Of Results

2018-01-03 seekingalpha
Today we will discuss the latest update from Achaogen (AKAO). AKAO shares surged in early trading on Tuesday after the clinical-stage biotech company moved a step closer to bringing its lead drug candidate, plazomicin, into the market. According to Blake Wise, Achaogen’s CEO, the number of confirmed cases of CRE annually in the U.S. alone total at least 70,000. More important, Wise noted is that the number is projected to double by 2022. (224-6)

ROTY Edition 1 Volume 66: GW Pharmaceuticals Gets Closer To The Finish Line - And Other Updates

2017-12-28 seekingalpha
ROTY has gotten off to a great start and much of that is due to support from readers. In coming months the discussion will shift to future formats and changes. (521-2)

Nexthera Capital Lp - All Holdings - 13F 13D 13G Filings -

Nexthera Capital Lp has disclosed 38 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 388,737,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Nexthera Capital Lp's top holdings are SPDR S&P Biotech ETF (NYSE:XBI) , Seattle Genetics, Inc. (NASDAQ:SGEN) , Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) , Clovis Oncology, Inc. (254-2)

7 Hot Healthcare Stocks Set to Double in 2018

2017-12-27 investorplace
For investors looking for huge returns, these healthcare stocks to buy may well be the answer. While these stocks are inevitably risky with a lot riding on key clinical results, the results can be spectacular if trials succeed. For example, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) shares are up over 500% in the past six months following stunning Non-alcoholic Steatohepatitis (NASH) data. (373-14)

Achaogen: Rebound Likely In 2018

2017-12-24 seekingalpha
Continued weakness in the space highlighted by the bargain sale of The Medicines Company's antibiotic portfolio worked against the stock in 2017. (133-62)

Biotechs: Not So 'Darn Scary' After All

2017-12-20 seekingalpha
We interviewed SA authors and seasoned biotech investors Terry Chrisomalis and Jerome Verony, who explain how they and their Marketplace communities do it. (291-5)

Baker Bros Advisors LP Upped By $4.67 Million Its Achaogen (AKAO) Position; Fti Consulting (FCN) Has 1 Sentiment - Herald KS

2017-12-19 heraldks
FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company has market cap of $1.60 billion. The companyÂ’s Corporate Finance & Restructuring segment provides business transformation, turnaround and restructuring, interim management, transaction, valuation and financial advisory, dispute advisory, and tax services, as well as mergers and acquisitions , and M & A integration services. (112-4)

Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria (NASDAQ:AKAO)

2017-12-16 investors.achaogen
The Bill & Melinda Gates Foundation is committing up to $20 million in grant funding and equity investment to further the development of an antibody platform and discovery of monoclonal antibody candidates against gram-negative bacteria, including those that cause neonatal sepsis (54-4)

Stock Research Report

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. Achaogen is researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics.

On December 12, 2016, the company announced positive data from its two Phase 3 clinical trials for plazomicin. The firs...

Click for full article
CUSIP: 004449104